Bentazepam

In this article, we will explore the fascinating world of Bentazepam. From its origins to its relevance today, we will dive into the most important aspects of Bentazepam. We will analyze its impact on society, its evolution over time and possible future implications. Through a detailed and critical look, we will try to unravel the mysteries that surround Bentazepam, offering the reader a complete and enriching perspective on this topic.

Bentazepam
Clinical data
Trade namesTiadipona (ES)
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral (tablets)
ATC code
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
MetabolismHepatic
Elimination half-life2–4 hours
ExcretionRenal
Identifiers
  • 5-phenyl-3,4,6,7,8,9-hexahydro-benzothiolodiazepin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.123.659 Edit this at Wikidata
Chemical and physical data
FormulaC17H16N2OS
Molar mass296.39 g·mol−1
3D model (JSmol)
  • O=C1CN=C(C2=CC=CC=C2)C3=C(N1)SC4=C3CCCC4
  • InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20) checkY
  • Key:AIZFEOPQVZBNGH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bentazepam (also known as Thiadipone, Tiadipona) is a thienodiazepine which is a benzodiazepine analog.

It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around 2,5 hours after oral administration. The elimination half-life is between approximately 2–4 hours. Bentazepam is effective as an anxiolytic.

A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure. Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea and drug-induced lymphocytic colitis has been associated with bentazepam. Severe liver damage and hepatitis has also been associated with bentazepam. Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.

See also

References

  1. ^ DE 2005276 
  2. ^ a b Gonzalez López F, Mariño EL, Dominguez-Gil A (September 1986). "Pharmacokinetics of tiadipone: a new anxiolytic". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 24 (9): 482–4. PMID 2877954.
  3. ^ Mariño EL, Fernandez Lastra C, Gonzalez Lopez F, Dominguez-Gil A, Garcia Santalla JL, Vorca G, et al. (November 1987). "Parametrization by non-linear regression and bayesian estimation of bentazepam in a multiple dosage regimen in humans". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 25 (11): 627–32. PMID 3429066.
  4. ^ Colino CI, Lastra CF, López FG, Ledesma A, Mariño EL (November 1991). "Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 29 (11): 457–62. PMID 1800395.
  5. ^ Rivas López FA, López Soriano F, Mendoza Cerezo A, Jiménez Ferré J, Azurmendi Rodríguez JI, de la Rubia Nieto MA (1989). "". Revista Espanola de Anestesiologia y Reanimacion. 36 (1): 48–50. PMID 2565591.
  6. ^ Honorato J, Rubio A, Tristán C, Otero FJ, Garrido J (1990). "". Revista de Medicina de la Universidad de Navarra. 34 (2): 80–8. PMID 1983365.
  7. ^ Fernández-Bañares F, Salas A, Esteve M, Espinós J, Forné M, Viver JM (February 2003). "Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up". The American Journal of Gastroenterology. 98 (2): 340–7. doi:10.1111/j.1572-0241.2003.07225.x. PMID 12591052. S2CID 1983209.
  8. ^ de-la-Serna C, Gil-Grande LA, Sanromán AL, Gonzalez M, Ruiz-del-Arbol L, Garcia Plaza A (December 1997). "Bentazepam-induced hepatic bridging necrosis". Journal of Clinical Gastroenterology. 25 (4): 710–1. doi:10.1097/00004836-199712000-00042. PMID 9451703.
  9. ^ Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y, Pachkoria K, et al. (December 2006). "Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry". Hepatology. 44 (6): 1581–8. doi:10.1002/hep.21424. PMID 17133470. S2CID 9067701.
  10. ^ Tuca A (2003). "Utilidad clinica del acetato de megestrol para la ganancia de peso en los enfermos con neoplasia y caquexia". Medicina Clinica (in Spanish). 120 (17): 678. doi:10.1157/13047309. Archived from the original on 2018-09-16. Retrieved 2009-09-18.
  11. ^ Andrade RJ, Lucena MI, Alcantara R, Fraile JM (April 1994). "Bentazepam-associated chronic liver disease". Lancet. 343 (8901): 860. doi:10.1016/S0140-6736(94)92065-6. PMID 7908109. S2CID 33991843.
  12. ^ Andrade RJ, Lucena MI, Aguilar J, Lazo MD, Camargo R, Moreno P, et al. (July 2000). "Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity". Digestive Diseases and Sciences. 45 (7): 1400–4. doi:10.1023/A:1005520523502. PMID 10961721.